UTHR
United Therapeutics Corporation
Price as of Jul 20, 2026
UTHR earnings
United Therapeutics Corporation earnings
Reported EPS and revenue history, upcoming estimates and available earnings-call summaries.
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 6, 2026 | $7.00 | $5.82 | -16.9% | $782M | -2.0% |
| Feb 25, 2026 | $6.78 | $7.70 | +13.6% | $790M | -0.6% |
| Oct 29, 2025 | $6.89 | $7.16 | +3.9% | $800M | -1.9% |
| Jul 30, 2025 | $7.29 | $6.41 | -12.1% | $799M | -0.4% |
| Apr 30, 2025 | $6.29 | $6.63 | +5.4% | $794M | +2.0% |
| Feb 26, 2025 | $6.40 | $6.19 | -3.3% | $736M | +0.2% |
| Oct 30, 2024 | $6.43 | $6.39 | -0.6% | $749M | +3.6% |
| Jul 31, 2024 | $6.40 | $5.85 | -8.6% | $715M | +3.3% |
| May 1, 2024 | $5.65 | $6.17 | +9.2% | $678M | +8.6% |
| Feb 21, 2024 | $4.19 | $4.36 | +4.1% | $615M | +6.7% |
| Nov 1, 2023 | $5.04 | $5.38 | +6.7% | $609M | +3.7% |
| Aug 2, 2023 | $4.51 | $5.24 | +16.2% | $597M | +13.8% |
Earnings call summary
Q1 FY2026 · May 6, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
• Martine mentioned two therapeutics in IPF with Tyveso and PAH with Relenopeg having shown better clinical outcomes. • Michael talked about first quarter revenue, Kaideso revenue, Tyveso DPI growth, competitive landscape, underlying demand metrics, Salesforce investments, IPF regulatory filing plans, and commercial goals. • Pat and others discussed details on RALPi development, formulation, and regulatory aspects
Guidance
• Relenopeg and IPF indication expected to put the company on path to more than double revenues over next few years. • Anticipated FDA approvals for Rolenapeg and IPF therapies with launch timelines mentioned. • Plan to double down on relentless innovation, proven experience, and patient obsession for growth
Segment performance
For the first quarter of 2026, total revenue was $782 million. Kaideso total revenue was $458 million. Tyveso DPI contributed 9% year-over-year growth. Relenopeg and Tyveso for IPF are expected to drive revenue growth with revenue run rate going to $4 billion by end of 2027. The inhaled formulation of RALDPI is in stealth mode and foreseen to be a big product
Analyst Q&A
Q: On IPF regulatory filing and JASCADE,
A: Lee discussed bridging strategy for IPF with Tyvesa BPI and Michael talked about JASCADE as proxy for pent-up demand in IPF.
Q: On commercial strategy and peak sales timing,
A: Michael said will provide more granularity as they build out forecast.
Q: On Rwanda PEG DPI,
A: Pat talked about RALPi development progress, re-IND engagement, and Phase 1 study plan.
Q: On REL-PAI development program,
A: Pat talked about timing and pursuing approval with solid dose.
Q: On Rolano Peg BPI formulation,
A: Pat talked about leveraging Mankind's Crystal Carrier IP.
Q: On IPF formulations and regulatory strategy,
A: Michael talked about multiple shots on goal strategy and Lee/Pat talked about regulatory path.
Q: On PHCOPD study,
A: Lee talked about PHCOPD study plans with tricosteal SMI and phases of study
Earnings history is derived from company filings and calendar data. Call summaries are grouped by reporting period. Latest covered event: 2026-07-29.